{"entity": "researcher", "timestamp": "2026-08-20T20:49:03.909Z", "family": "Amini", "given": "Rose-Marie", "initials": "RM", "orcid": "0000-0003-0901-5252", "affiliations": ["Clinical and Experimental Pathology, Department of Immunology, Genetics and Pathology, Uppsala University and University Hospital, Uppsala, Sweden."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/ae2f974dbafa4cdbbe268c635adcd278.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/ae2f974dbafa4cdbbe268c635adcd278"}}, "publications": [{"entity": "publication", "iuid": "84b68e9019d34d52aecd219380bdb7bb", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/84b68e9019d34d52aecd219380bdb7bb.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/84b68e9019d34d52aecd219380bdb7bb"}}, "title": "Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients.", "authors": [{"family": "Sar\u00e9n", "given": "Tina", "initials": "T", "orcid": "0000-0001-5227-6779", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/ed75a6dcbb9940e49481280af6183d69.json"}}, {"family": "Ramachandran", "given": "Mohanraj", "initials": "M", "orcid": "0000-0003-2685-0575", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/dd947633edf949aba9e680e63a1e178b.json"}}, {"family": "Gammelg\u00e5rd", "given": "Gustav", "initials": "G", "orcid": "0009-0008-5522-0103", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/23c14e3d3bf445a7b3ff9d45eafbc5e1.json"}}, {"family": "L\u00f6vgren", "given": "Tanja", "initials": "T", "orcid": "0000-0003-2170-0682", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f4a04a7c6e904ff0945c058fcaa3151d.json"}}, {"family": "Mirabello", "given": "Claudio", "initials": "C", "orcid": "0000-0001-7868-034X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f4ca88bb3cf24e2591c447ec929502e6.json"}}, {"family": "Bj\u00f6rklund", "given": "\u00c5sa K", "initials": "\u00c5K", "orcid": "0000-0003-2224-7090", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/1cfd05eeb19640eea44f996699f998f0.json"}}, {"family": "Wikstr\u00f6m", "given": "Kristina", "initials": "K", "orcid": "0009-0000-1027-2534", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/1c1933e2ca1f494998c1681623af5ce9.json"}}, {"family": "Hashemi", "given": "Jamileh", "initials": "J", "orcid": "0000-0002-4997-3765", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/d2e89291626e4f3eb73835d352bf67f4.json"}}, {"family": "Freyhult", "given": "Eva", "initials": "E", "orcid": "0000-0003-0226-1047", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/13486bb11790445fa37f592a42e6a7ed.json"}}, {"family": "Ahlstr\u00f6m", "given": "H\u00e5kan", "initials": "H", "orcid": "0000-0002-8701-969X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/7e0504d2b7e14415b7c20229df25c0aa.json"}}, {"family": "Amini", "given": "Rose-Marie", "initials": "RM", "orcid": "0000-0003-0901-5252", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/ae2f974dbafa4cdbbe268c635adcd278.json"}}, {"family": "Hagberg", "given": "Hans", "initials": "H", "orcid": "0000-0001-7855-2452", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f525112ab8e94ce790be483b56d7cbd6.json"}}, {"family": "Loskog", "given": "Angelica", "initials": "A", "orcid": "0000-0001-8583-6138", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/572e5b01b3bd48779252b9020732cb09.json"}}, {"family": "Enblad", "given": "Gunilla", "initials": "G", "orcid": "0000-0002-0594-724X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/2a285fb437854e2c998356b1a3124416.json"}}, {"family": "Essand", "given": "Magnus", "initials": "M", "orcid": "0000-0002-9725-0422", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/a2e56cdd77634c01ab6d98dea8c60430.json"}}], "type": "journal article", "published": "2023-10-13", "journal": {"title": "Clin. Cancer Res.", "issn": "1557-3265", "volume": "29", "issue": "20", "pages": "4139-4152", "issn-l": "1078-0432"}, "abstract": "Although CD19 chimeric antigen receptor T cells (CAR-T) therapy has shown remarkable success in B-cell malignancies, a substantial fraction of patients do not obtain a long-term clinical response. This could be influenced by the quality of the individual CAR-T infusion product. To shed some light on this, clinical outcome was correlated to characteristics of CAR-T infusion products.\n\nIn this phase II study, patients with B-cell lymphoma (n = 23) or leukemia (n = 1) received one or two infusions of third-generation CD19-directed CAR-Ts (2 \u00d7 108/m2). The clinical trial was registered at clinicaltrials.gov: NCT03068416. We investigated the transcriptional profile of individual CD19 CAR-T infusion products using targeted single-cell RNA sequencing and multicolor flow cytometry.\n\nTwo CAR-T infusions were not better than one in the settings used in this study. As for the CAR-T infusion products, we found that effector-like CD8+CAR-Ts with a high polyfunctionality, high cytotoxic and cytokine production profile, and low dysfunctional signature were associated with clinical response. An extended ex vivo expansion time during CAR-T manufacturing negatively influenced the proportion of effector CD8+CAR-Ts in the infusion product.\n\nWe identified cell-intrinsic characteristics of effector CD8+CAR-Ts correlating with response that could be used as an indicator for clinical outcome. The results in the study also serve as a guide to CAR-T manufacturing practices.", "doi": "10.1158/1078-0432.CCR-23-0178", "pmid": "37540566", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC10570681"}, {"db": "pii", "key": "728314"}, {"db": "ClinicalTrials.gov", "key": "NCT03068416"}, {"db": "figshare", "key": "20208764"}], "notes": [], "created": "2026-08-20T12:12:20.782Z", "modified": "2026-08-20T12:12:21.097Z"}, {"entity": "publication", "iuid": "5396502ba12f4390941c8aafa0a37ea9", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/5396502ba12f4390941c8aafa0a37ea9.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/5396502ba12f4390941c8aafa0a37ea9"}}, "title": "PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS.", "authors": [{"family": "Abdulla", "given": "Maysaa", "initials": "M"}, {"family": "Alexsson", "given": "Andrei", "initials": "A"}, {"family": "Sundstr\u00f6m", "given": "Christer", "initials": "C"}, {"family": "Ladenvall", "given": "Claes", "initials": "C"}, {"family": "Mansouri", "given": "Larry", "initials": "L"}, {"family": "Lindskog", "given": "Cecilia", "initials": "C"}, {"family": "Berglund", "given": "Mattias", "initials": "M"}, {"family": "Cavelier", "given": "Lucia", "initials": "L"}, {"family": "Enblad", "given": "Gunilla", "initials": "G", "orcid": "0000-0002-0594-724X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/2a285fb437854e2c998356b1a3124416.json"}}, {"family": "Hollander", "given": "Peter", "initials": "P"}, {"family": "Amini", "given": "Rose-Marie", "initials": "RM", "orcid": "0000-0003-0901-5252", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/ae2f974dbafa4cdbbe268c635adcd278.json"}}], "type": "journal article", "published": "2021-04-00", "journal": {"title": "Acta Oncol", "issn": "1651-226X", "volume": "60", "issue": "4", "pages": "531-538", "issn-l": "0284-186X"}, "abstract": "Programmed cell death 1 (PD-1) and its ligands PD-L1 and PD-L2, as well as Indoleamine 2,3-deoxygenase (IDO1) can be expressed both by tumor and microenvironmental cells and are crucial for tumor immune escape. We aimed to evaluate the role of PD-1, its ligands and IDO1 in a cohort of patients with primary diffuse large B-cell lymphoma of the CNS (PCNSL).\n\nTissue microarrays (TMAs) were constructed in 45 PCNSL cases. RNA extraction from whole tissue sections and RNA sequencing were successfully performed in 33 cases. Immunohistochemical stainings for PD-1, PD-L1/paired box protein 5 (PAX-5), PD-L2/PAX-5 and IDO1, and Epstein-Barr virus encoding RNA (EBER) in situ hybridization were analyzed.\n\nHigh proportions of PD-L1 and PD-L2 positive tumor cells were observed in 11% and 9% of cases, respectively. High proportions of PD-L1 and PD-L2 positive leukocytes were observed in 55% and 51% of cases, respectively. RNA sequencing revealed that gene expression of IDO1 was high in patients with high proportion of PD-L1 positive leukocytes (p = .01). Protein expression of IDO1 in leukocytes was detected in 14/45 cases, in 79% of these cases a high proportion of PD-L1 positive leukocytes was observed. Gene expression of IDO1 was high in EBER-positive cases (p = .0009) and protein expression of IDO1 was detected in five of six EBER-positive cases.\n\nOur study shows a significant association between gene and protein expression of IDO1 and protein expression of PD-L1 in the tumor microenvironment of PCNSL, possibly of importance for prediction of response to immunotherapies.", "doi": "10.1080/0284186X.2021.1881161", "pmid": "33579170", "labels": [], "xrefs": [], "notes": [], "created": "2026-08-20T09:34:40.874Z", "modified": "2026-08-20T09:34:40.934Z"}, {"entity": "publication", "iuid": "2a39101d25024413973f880034a6b610", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/2a39101d25024413973f880034a6b610.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/2a39101d25024413973f880034a6b610"}}, "title": "A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.", "authors": [{"family": "Enblad", "given": "Gunilla", "initials": "G"}, {"family": "Karlsson", "given": "Hannah", "initials": "H"}, {"family": "Gammelg\u00e5rd", "given": "Gustav", "initials": "G"}, {"family": "Wenthe", "given": "Jessica", "initials": "J", "orcid": "0000-0003-4385-7568", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/bc4cbbff70a944af8f477c2a78f79c98.json"}}, {"family": "L\u00f6vgren", "given": "Tanja", "initials": "T", "orcid": "0000-0003-2170-0682", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f4a04a7c6e904ff0945c058fcaa3151d.json"}}, {"family": "Amini", "given": "Rose Marie", "initials": "RM", "orcid": "0000-0003-0901-5252", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/ae2f974dbafa4cdbbe268c635adcd278.json"}}, {"family": "Wikstrom", "given": "Kristina I", "initials": "KI"}, {"family": "Essand", "given": "Magnus", "initials": "M"}, {"family": "Savoldo", "given": "Barbara", "initials": "B"}, {"family": "Hallb\u00f6\u00f6k", "given": "Helene", "initials": "H"}, {"family": "H\u00f6glund", "given": "Martin", "initials": "M"}, {"family": "Dotti", "given": "Gianpietro", "initials": "G"}, {"family": "Brenner", "given": "Malcolm K", "initials": "MK"}, {"family": "Hagberg", "given": "Hans", "initials": "H"}, {"family": "Loskog", "given": "Angelica", "initials": "A", "orcid": "0000-0001-8583-6138", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/572e5b01b3bd48779252b9020732cb09.json"}}], "type": "clinical trial, phase i", "published": "2018-12-15", "journal": {"title": "Clin. Cancer Res.", "issn": "1557-3265", "volume": "24", "issue": "24", "pages": "6185-6194", "issn-l": "1078-0432"}, "abstract": "The chimeric antigen receptor (CAR) T-cell therapy has been effective for patients with CD19+ B-cell malignancies. Most studies have investigated the second-generation CARs with either CD28 or 4-1BB costimulatory domains in the CAR receptor. Here, we describe the first clinical phase I/IIa trial using third-generation CAR T cells targeting CD19 to evaluate safety and efficacy.\n\nFifteen patients with B-cell lymphoma or leukemia were treated with CAR T cells. The patients with lymphoma received chemotherapy during CAR manufacture and 11 of 15 were given low-dose cyclophosphamide and fludarabine conditioning prior to CAR infusion. Peripheral blood was sampled before and at multiple time points after CAR infusion to evaluate the persistence of CAR T cells and for immune profiling, using quantitative PCR, flow cytometry, and a proteomic array.\n\nTreatment with third-generation CAR T cells was generally safe with 4 patients requiring hospitalization due to adverse reactions. Six of the 15 patients had initial complete responses [4/11 lymphoma and 2/4 acute lymphoblastic leukemia (ALL)], and 3 of the patients with lymphoma were in remission at 3 months. Two patients are still alive. Best predictor of response was a good immune status prior to CAR infusion with high IL12, DC-Lamp, Fas ligand, and TRAIL. Responding patients had low monocytic myeloid-derived suppressor cells (MDSCs; CD14+CD33+HLA-DR-) and low levels of IL6, IL8, NAP3, sPDL1, and sPDL2.\n\nThird-generation CARs may be efficient in patients with advanced B-cell lymphoproliferative malignancy with only modest toxicity. Immune profiling pre- and posttreatment can be used to find response biomarkers.", "doi": "10.1158/1078-0432.CCR-18-0426", "pmid": "30097433", "labels": [], "xrefs": [{"db": "pii", "key": "1078-0432.CCR-18-0426"}, {"db": "EudraCT", "key": "2013-001393-19"}, {"db": "ClinicalTrials.gov", "key": "NCT02132624"}], "notes": [], "created": "2026-08-20T12:12:04.617Z", "modified": "2026-08-20T12:12:04.768Z"}]}